Modalis Therapeutics

4883.TTSE GROWTHPharmaceutical

Key numbers · FY ended 2022-12

Revenue¥41m+3581.8% YoY Operating income−¥2.2bn—Net income (owners)−¥2.2bn—Total assets¥3.0bn-19.7% YoY EPS (basic)¥-27.86+2.5% YoY

Full financial history and reports →

Stock price4883 · View chart ↗

Open the price chart on TradingView.

Latest filings

Thu, Oct 22 · JST1 filing

11:205% STAKEModalis Therapeutics · Evo Fund + 1 joint holder · 8.96% → 7.61%−1.35pp

Fri, Sep 18 · JST1 filing

14:205% STAKEModalis Therapeutics · Evo Fund + 1 joint holder · 10.28% → 9.02%−1.26pp

Thu, Sep 17 · JST1 filing

10:115% STAKEModalis Therapeutics · Evo Fund + 1 joint holder · 14.23% → 10.28%−3.95pp

Tue, Aug 18 · JST1 filing

11:305% STAKEModalis Therapeutics · Evo Fund + 1 joint holder · 16.20% → 15.16%−1.04pp

Thu, Jul 30 · JST1 filing

15:475% STAKEModalis Therapeutics · Evo Fund + 1 joint holder · 17.46% → 16.20%−1.26pp

All filings →

Major holders (5%+) · 3

Holder	Stake	Change	Filed
Evo Fund	7.61%	-1.35pp	2026-10-22
Life Science Innovation Management Inc.	6.28%	-9.02pp	2025-08-12
LSIM Inc.	5.02%	-0.21pp	2026-05-27

Each holder's own ratio from its most recent large-shareholding report.